Beam Therapeutics(纳斯达克股票代码:BEAM)今日披露其2026年第二季度的财务表现,同时对外宣布,其针对α-1抗胰蛋白酶缺乏症(AATD)的研究性疗法Beam-302,已在全球关键性临床试验队列中完成首例患者给药。这一里程碑事件,标志着该候选药物在开发进程中迈出了至关重要的一步。
Beam Therapeutics(纳斯达克股票代码:BEAM)今日披露其2026年第二季度的财务表现,同时对外宣布,其针对α-1抗胰蛋白酶缺乏症(AATD)的研究性疗法Beam-302,已在全球关键性临床试验队列中完成首例患者给药。这一里程碑事件,标志着该候选药物在开发进程中迈出了至关重要的一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.